Cargando…
Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop
The objective of this study was to quantify the increase in efficacy during the first four cycles of treatment with botulinum toxin type/A (BoNT/A) in 24 free-walking BoNT/A naïve adult patients with post-stroke hemispasticity and spastic foot drop. Patients were followed over 390 days and received...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310361/ https://www.ncbi.nlm.nih.gov/pubmed/34357938 http://dx.doi.org/10.3390/toxins13070466 |
_version_ | 1783728743259308032 |
---|---|
author | Hefter, Harald Nickels, Werner Rosenthal, Dietmar Samadzadeh, Sara Albrecht, Philipp |
author_facet | Hefter, Harald Nickels, Werner Rosenthal, Dietmar Samadzadeh, Sara Albrecht, Philipp |
author_sort | Hefter, Harald |
collection | PubMed |
description | The objective of this study was to quantify the increase in efficacy during the first four cycles of treatment with botulinum toxin type/A (BoNT/A) in 24 free-walking BoNT/A naïve adult patients with post-stroke hemispasticity and spastic foot drop. Patients were followed over 390 days and received five injections of 800 U aboBoNT/A every three months. Patients assessed the treatment effect at eight visits using a global assessment scale, physicians scored the muscle tone at the ankle joint, measured active and passive ranges of motion (aRoMs, pRoMs) at the knee and ankle joint and determined the distance patients succeeded to walk during a minute. Patients’ assessments significantly (p < 0.006) increased with time and significantly correlated with all parameters measured. The best correlation (r = 0.927; p < 0.0001) was found with the sum of the aRoMs of knee and ankle joint. After one year of treatment outcome measures were better than and significantly correlated with the peak effect of the first injection. This correlation was higher for pRoMs (r = 0.855; p < 0.00001) compared to aRoMs (r = 0.567; p < 0.009). When BoNT/A treatment of the spastic foot in chronic hemispasticity is performed regularly every three months for at least one year, patients will experience a significant increase of benefit beyond the first treatment, but have to learn how to adapt to and use the new degree of freedom induced by the injections. |
format | Online Article Text |
id | pubmed-8310361 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83103612021-07-25 Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop Hefter, Harald Nickels, Werner Rosenthal, Dietmar Samadzadeh, Sara Albrecht, Philipp Toxins (Basel) Article The objective of this study was to quantify the increase in efficacy during the first four cycles of treatment with botulinum toxin type/A (BoNT/A) in 24 free-walking BoNT/A naïve adult patients with post-stroke hemispasticity and spastic foot drop. Patients were followed over 390 days and received five injections of 800 U aboBoNT/A every three months. Patients assessed the treatment effect at eight visits using a global assessment scale, physicians scored the muscle tone at the ankle joint, measured active and passive ranges of motion (aRoMs, pRoMs) at the knee and ankle joint and determined the distance patients succeeded to walk during a minute. Patients’ assessments significantly (p < 0.006) increased with time and significantly correlated with all parameters measured. The best correlation (r = 0.927; p < 0.0001) was found with the sum of the aRoMs of knee and ankle joint. After one year of treatment outcome measures were better than and significantly correlated with the peak effect of the first injection. This correlation was higher for pRoMs (r = 0.855; p < 0.00001) compared to aRoMs (r = 0.567; p < 0.009). When BoNT/A treatment of the spastic foot in chronic hemispasticity is performed regularly every three months for at least one year, patients will experience a significant increase of benefit beyond the first treatment, but have to learn how to adapt to and use the new degree of freedom induced by the injections. MDPI 2021-07-02 /pmc/articles/PMC8310361/ /pubmed/34357938 http://dx.doi.org/10.3390/toxins13070466 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hefter, Harald Nickels, Werner Rosenthal, Dietmar Samadzadeh, Sara Albrecht, Philipp Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop |
title | Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop |
title_full | Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop |
title_fullStr | Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop |
title_full_unstemmed | Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop |
title_short | Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop |
title_sort | continuous increase of efficacy under repetitive injections of botulinum toxin type/a beyond the first treatment for adult spastic foot drop |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310361/ https://www.ncbi.nlm.nih.gov/pubmed/34357938 http://dx.doi.org/10.3390/toxins13070466 |
work_keys_str_mv | AT hefterharald continuousincreaseofefficacyunderrepetitiveinjectionsofbotulinumtoxintypeabeyondthefirsttreatmentforadultspasticfootdrop AT nickelswerner continuousincreaseofefficacyunderrepetitiveinjectionsofbotulinumtoxintypeabeyondthefirsttreatmentforadultspasticfootdrop AT rosenthaldietmar continuousincreaseofefficacyunderrepetitiveinjectionsofbotulinumtoxintypeabeyondthefirsttreatmentforadultspasticfootdrop AT samadzadehsara continuousincreaseofefficacyunderrepetitiveinjectionsofbotulinumtoxintypeabeyondthefirsttreatmentforadultspasticfootdrop AT albrechtphilipp continuousincreaseofefficacyunderrepetitiveinjectionsofbotulinumtoxintypeabeyondthefirsttreatmentforadultspasticfootdrop |